
SeaStar Medical's QUELIMMUNE Shows Promise in Treating Pediatric AKI
SeaStar Medical's QUELIMMUNE device, approved by the FDA, significantly reduces mortality rates in pediatric patients with acute kidney injury (AKI) by targeting the cytokine storm at its source.
Read full story






















